Skip to main content


Table 3 Emerging targets with clinical significance in PC

From: Emerging therapeutic agents for genitourinary cancers

Molecular target Class Trial Disease setting Agent Experimental treatment Study phase Estimated completion
Hormonal Therapy Second-generation ADT NCT03098836 mCRPC Apalutamide Apalutamide + abiraterone Phase II June 2021
NCT02106507 mCRPC Apalutamide Apalutamide +everolimus Phase I April 2020
NCT02489318 (TITAN) mCSPC Apalutamide Apalutamide + ADT Phase III July 2022
New-generation ADT NCT02200614 (ARAMIS) nmCRPC Darolutamide Darolutamide Phase III June 2020
AR inhibitor NCT02445976 CRPC Progressing on Enzalutamide or Abiraterone Seviteronel Seviteronel Phase II January 2019*
NCT02012920 CRPC Seviteronel Seviteronel Phase II January 2019*
Tumor Vaccine Dendritic Cells NCT02111577 (VIABLE) mCRPC DCVAC DCVAC Phase III June 2020
PD-L1 and CTLA-4 CPI NCT02861573 (KEYNOTE-365) mCRPC Pembrolizumab + olaparib or Pembrolizumab + docetaxel + prednisone or Pembrolizumab + enzalutamide Phase I May 2022
NCT02985957 (CheckMate-650) mCRPC Nivolumab + Ipilimumab Phase II March 2022
PD-L1 NCT02787005 (KEYNOTE-199) mCRPC Pembrolizumab Pembrolizumab monotherapy or Pembrolizumab + enzalutamide Phase II December 2020
PARP Inhibitor DNA Repair Inhibition NCT03834519 (KEYLYNK-010) mCRPC Pembrolizumab + olaparib Pembrolizumab + olaparib Phase III September 2022
NCT03732820 Previously-untreated mCRPC Abiraterone + olaparib Abiraterone Phase III August 2022
Radioisotope NCT03737370 mCRPC Radium-223 Radium-223 + docetaxel Phase I October 2021
ACTRN12615000912583** (LuPSMA Trial) mCRPC 177Lutetium Phase I/II N/A
  1. All trial information obtained through publicly accessible
  2. *Results pending
  3. **Trial filed in Australia New Zealand Clinical trials registry,